Patents by Inventor Christina DILLMANN

Christina DILLMANN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • N-TERMINALLY TRUNCATED INTERLEUKIN-38
    Publication number: 20200277349
    Abstract: The present invention pertains to an N-terminally truncated interleukin (IL)-38 protein, or functional variants thereof, as well as to nucleic acids and vectors encoding the truncated IL-38 peptide and recombinant cells comprising these nucleic acids or vectors. The invention shows that IL-38 is N-terminally processed and that the truncated version of the cytokine acts as an antagonist of immune activation in macrophages. This indicates a use of the truncated cytokine in the treatment and prevention of autoimmune disorders. The invention further provides pharmaceutical compositions comprising the truncated IL-38 protein, and method for screening modulators of the function of truncated IL-38.
    Type: Application
    Filed: March 2, 2020
    Publication date: September 3, 2020
    Inventors: Andreas WEIGERT, Javier MORA, Bernhard BRUNE, Christina DILLMANN, Michael John PARNHAM, Gerd GEISSLINGER
  • N-terminally truncated interleukin-38
    Patent number: 10618946
    Abstract: The present invention pertains to an N-terminally truncated interleukin (IL)-38 protein, or functional variants thereof, as well as to nucleic acids and vectors encoding the truncated IL-38 peptide and recombinant cells comprising these nucleic acids or vectors. The invention shows that IL-38 is N-terminally processed and that the truncated version of the cytokine acts as an antagonist of immune activation in macrophages. This indicates a use of the truncated cytokine in the treatment and prevention of autoimmune disorders. The invention further provides pharmaceutical compositions comprising the truncated IL-38 protein, and method for screening modulators of the function of truncated IL-38.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: April 14, 2020
    Assignee: FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
    Inventors: Andreas Weigert, Javier Mora, Bernhard Brune, Christina Dillmann, Michael John Parnham, Gerd Geisslinger
  • N-TERMINALLY TRUNCATED INTERLEUKIN-38
    Publication number: 20170218039
    Abstract: The present invention pertains to an N-terminally truncated interleukin (IL)-38 protein, or functional variants thereof, as well as to nucleic acids and vectors encoding the truncated IL-38 peptide and recombinant cells comprising these nucleic acids or vectors. The invention shows that IL-38 is N-terminally processed and that the truncated version of the cytokine acts as an antagonist of immune activation in macrophages. This indicates a use of the truncated cytokine in the treatment and prevention of autoimmune disorders. The invention further provides pharmaceutical compositions comprising the truncated IL-38 protein, and method for screening modulators of the function of truncated IL-38.
    Type: Application
    Filed: July 14, 2015
    Publication date: August 3, 2017
    Inventors: Andreas WEIGERT, Javier MORA, Bernhard BRÜNE, Christina DILLMANN, Michael John PARNHAM, Gerd GEISSLINGER